Abstract
Major depressive disorder (MDD) is a prevalent and recurring mental disorder often associated with high rates of non-recovery and substantial consequences on psychosocial outcome. Cognitive impairment is one of the most frequent residual symptoms of MDD. The persistence of cognitive impairment even in remitted phases of the disorder, notably in the domains of executive function and attention, suggests that it may serve as a mediational nexus between MDD and poor functional outcome, accounting for occupational and relational difficulties regardless of clinical improvement on depressive symptoms. The critical impact of cognitive deficits on psychosocial dysfunction invites clinicians to regularly screen and assess cognition across multiple domains, taking into account also clinical correlates of cognitive dysfunction in MDD. Despite the availability of several instruments for the screening and assessment of cognitive dysfunction, the lack of consensus guiding the choice of appropriate instruments increases the likelihood to underestimate cognitive dysfunction in MDD in clinical settings. On the other hand, the unsatisfactory effect of most antidepressant treatments on cognitive deficits for many individuals with MDD calls for the development of genuinely novel therapeutic agents with potential to target cognitive dysfunction. Notwithstanding the necessity of further investigations, this review indicates that neuropsychological deficits (e.g., impaired executive functions) are stable markers of MDD and underscores the need for the development of integrative and multi-modal strategies for the prevention and treatment of neuropsychological impairments in MDD.
Keywords: Antidepressant, cognitive dysfunction, psychosocial functioning, Major depressive disorder, recovery, treatment.
CNS & Neurological Disorders - Drug Targets
Title:Cognitive Dysfunction in Major Depressive Disorder: A State-of-the-Art Clinical Review
Volume: 13 Issue: 10
Author(s): Beatrice Bortolato, Andre F. Carvalho and Roger S. McIntyre
Affiliation:
Keywords: Antidepressant, cognitive dysfunction, psychosocial functioning, Major depressive disorder, recovery, treatment.
Abstract: Major depressive disorder (MDD) is a prevalent and recurring mental disorder often associated with high rates of non-recovery and substantial consequences on psychosocial outcome. Cognitive impairment is one of the most frequent residual symptoms of MDD. The persistence of cognitive impairment even in remitted phases of the disorder, notably in the domains of executive function and attention, suggests that it may serve as a mediational nexus between MDD and poor functional outcome, accounting for occupational and relational difficulties regardless of clinical improvement on depressive symptoms. The critical impact of cognitive deficits on psychosocial dysfunction invites clinicians to regularly screen and assess cognition across multiple domains, taking into account also clinical correlates of cognitive dysfunction in MDD. Despite the availability of several instruments for the screening and assessment of cognitive dysfunction, the lack of consensus guiding the choice of appropriate instruments increases the likelihood to underestimate cognitive dysfunction in MDD in clinical settings. On the other hand, the unsatisfactory effect of most antidepressant treatments on cognitive deficits for many individuals with MDD calls for the development of genuinely novel therapeutic agents with potential to target cognitive dysfunction. Notwithstanding the necessity of further investigations, this review indicates that neuropsychological deficits (e.g., impaired executive functions) are stable markers of MDD and underscores the need for the development of integrative and multi-modal strategies for the prevention and treatment of neuropsychological impairments in MDD.
Export Options
About this article
Cite this article as:
Bortolato Beatrice, Carvalho F. Andre and McIntyre S. Roger, Cognitive Dysfunction in Major Depressive Disorder: A State-of-the-Art Clinical Review, CNS & Neurological Disorders - Drug Targets 2014; 13 (10) . https://dx.doi.org/10.2174/1871527313666141130203823
DOI https://dx.doi.org/10.2174/1871527313666141130203823 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Imidazole Incorporated Semicarbazone Derivatives as a New Class of Anticonvulsants: Design, Synthesis and In-Vivo Screening
Medicinal Chemistry Formulation of Extended-Release Beads of Lamotrigine Based on Alginate and <i>Cassia fistula</i> Seed Gum by QbD Approach
Current Drug Delivery Molecular Mechanism of a Specific NLRP3 Inhibitor to Alleviate Seizure Severity Induced by Pentylenetetrazole
Current Molecular Pharmacology Glia: An Important Target for Anti-Inflammatory and Antidepressant Activity
Current Drug Targets Toxins Targeting Voltage-Activated Ca<sup>2+</sup> Channels and their Potential Biomedical Applications
Current Topics in Medicinal Chemistry Carnitine Metabolism and Deficit - When Supplementation is Necessary?
Current Pharmaceutical Biotechnology The Protective Effects of Natural Products on Blood-Brain Barrier Breakdown
Current Medicinal Chemistry Hybrid Imaging: Conclusions and Perspectives
Current Medical Imaging Carbonic Anhydrase I and II Inhibition with Natural Products: Abrus precatorius
Current Enzyme Inhibition Novel Therapeutic Strategies for Dementia
CNS & Neurological Disorders - Drug Targets Anti-Seizure Medications and Estradiol for Neuroprotection in Epilepsy: The 2013 Update
Recent Patents on CNS Drug Discovery (Discontinued) PDZ Domains at Excitatory Synapses: Potential Molecular Targets for Persistent Pain Treatment
Current Neuropharmacology Alpha7 Neuronal Nicotinic Receptor: A Pluripotent Target for Diseases of the Central Nervous System
CNS & Neurological Disorders - Drug Targets A Review on Possible Therapeutic Effect of Nigella sativa and Thymoquinone in Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets ORO-Dental Manifestations in West Syndrome
Current Topics in Medicinal Chemistry Substrates, Inhibitors and Activators of P-glycoprotein: Candidates for Radiolabeling and Imaging Perspectives
Current Topics in Medicinal Chemistry Curcumin Alleviates Cerebral Ischemia-reperfusion Injury by Inhibiting NLRP1-dependent Neuronal Pyroptosis
Current Neurovascular Research Study of Convolvulus pluricaulis for Antioxidant and Anticonvulsant Activity
Central Nervous System Agents in Medicinal Chemistry Pharmacological Histone Deacetylation Distinguishes Transcriptional Regulators
Current Topics in Medicinal Chemistry The Role of Extracellular Adenosine in Chemical Neurotransmission in the Hippocampus and Basal Ganglia: Pharmacological and Clinical Aspects
Current Topics in Medicinal Chemistry